Evidence map›Paper›PMID 42288627›Full record

ArticleScientific reports2026

A patient-specific induced pluripotent stem cell and neural stem cell resource for angelman syndrome with 15q11.2-q13 deletion.

Song Qu, Yue Wu, Pu Sun, Cui Song, Yanyan Wang

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Song QuDepartment of Medical Genetics, College of Basic Medical Science, Army Medical University, (Third Military Medical University), Chongqing, China.ORCID http://orcid.org/0009-0008-4149-2618
Yue WuDepartment of Medical Genetics, College of Basic Medical Science, Army Medical University, (Third Military Medical University), Chongqing, China.ORCID http://orcid.org/0009-0000-8740-7660
Pu SunDepartment of Pediatrics, Army Feature Medical Center, Army Medical University, (Third Military Medical University), Chongqing, China.ORCID http://orcid.org/0009-0008-2409-401X
Cui SongNational Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Children's Hospital of Chongqing Medical University, Chongqing, China. 400756@hospital.cqmu.edu.cn.ORCID http://orcid.org/0000-0002-6444-7763
Yanyan WangDepartment of Medical Genetics, College of Basic Medical Science, Army Medical University, (Third Military Medical University), Chongqing, China. yanyan_wang@tmmu.edu.cn.ORCID http://orcid.org/0000-0002-6312-206X

Funding

Key Project of Innovation and Development United Fund of Chongqing Natural Science Foundation CSTB2022NSCQ-LZX0029 to C.S.National Natural Science Foundation of China 82171852Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission cstc2021jcyj-msxmX0329
6 · The paper itself

Abstract

Angelman syndrome (AS) is a severe neurodevelopmental disorder most commonly caused by a maternal deletion of the 15q11.2-q13 region, resulting in loss of ubiquitin protein ligase E3A (UBE3A) function. The development of targeted therapies and a deeper understanding of AS pathogenesis require the availability of genetically accurate human models. Here, we generated and characterized a novel induced pluripotent stem cell (iPSC) line from peripheral blood mononuclear cells of a female pediatric patient with genetically confirmed deletion-type AS. The iPSC line displayed a normal karyotype, expressed key pluripotency markers, and demonstrated trilineage differentiation potential. Efficient generation of neural stem cells establishes a foundational cellular resource for future investigations of neuronal maturation and disease-specific phenotypes. This well-validated iPSC and NSC resource provides a valuable and clinically relevant platform for elucidating the molecular pathophysiology of AS in a genetically accurate human cellular context and for high-throughput screening of therapeutic compounds targeting the predominant population of patients with AS.

Indexed as

Angelman SyndromeChromosome DeletionInduced Pluripotent Stem CellsNeural Stem CellsCell DifferentiationCell LineChromosomes, Human, Pair 15FemaleHumansUbiquitin-Protein LigasesUBE3A protein, humanUbiquitin-Protein Ligases

Identifiers

PMID42288627
PMCPMC13540905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.